Genmab (GMAB) details employee RSU and warrant grants in 6-K

Rhea-AI Filing Summary

Genmab A/S submitted a Form 6-K as a foreign private issuer, furnishing a company announcement dated November 20, 2025 about the grant of restricted stock units and warrants to employees of Genmab.

The report is also incorporated by reference into several existing Genmab Form S-8 registration statements, making the announcement part of those employee equity compensation registrations.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF NOVEMBER 2025

COMMISSION FILE NUMBER 001-38976

Genmab A/S
(Exact name of Registrant as specified in its charter)

Carl Jacobsens Vej 30

2500 Valby

Denmark

+45 70 20 27 28
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F 

This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit			Description of Exhibit
99.1			Company Announcement Dated November 20, 2025: Grant of Restricted Stock Units and Warrants to Employees in Genmab

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			GENMAB A/S
			BY:			/s/ Anthony Pagano
						Name: Anthony Pagano
						Title: Executive Vice President & Chief Financial Officer

DATE: NOVEMBER 20, 2025

FAQ

What does Genmab A/S (GMAB) disclose in its November 2025 Form 6-K?

Genmab A/S discloses a company announcement dated November 20, 2025 concerning grants of restricted stock units and warrants to its employees. The Form 6-K also states that this information is incorporated by reference into several existing Genmab Form S-8 registration statements.

What equity awards are mentioned for Genmab A/S (GMAB) employees?

The content states that Genmab issued grants of restricted stock units and warrants to its employees. These instruments are typically used as long-term incentive compensation, aligning employee interests with shareholders by linking part of compensation to the company’s share performance over time.

How is the November 2025 Genmab (GMAB) 6-K linked to Form S-8 registrations?

The Form 6-K is deemed incorporated by reference into Genmab’s Form S-8 registration statements with several file numbers. This means the information about restricted stock unit and warrant grants becomes part of those employee share incentive plan registrations for U.S. securities law purposes.

What is the exhibit included with Genmab A/S (GMAB) November 2025 Form 6-K?

The exhibit listed is 99.1, described as a company announcement dated November 20, 2025 titled “Grant of Restricted Stock Units and Warrants to Employees in Genmab.” This exhibit contains the detailed announcement regarding the new employee equity grants.

Who signed the November 2025 Genmab A/S (GMAB) Form 6-K?

The Form 6-K is signed on behalf of Genmab A/S by Anthony Pagano, who is identified as Executive Vice President and Chief Financial Officer. His signature confirms that he is duly authorized to sign the report for the company under the Exchange Act.

What is the purpose of Genmab A/S (GMAB) filing a Form 6-K as a foreign private issuer?

Form 6-K is used by foreign private issuers like Genmab A/S to furnish material information to U.S. investors between annual reports. In this case, it communicates an employee equity grant announcement and formally incorporates that information into existing employee benefit registration statements.